Scrip Awards 2017 Entry Guide

The 13th Annual
29 November 2017 | London Hilton on Park Lane
www.scripawards.com2017
Scrip Awards
Entry Guide
Sponsored by Headline Sponsor
Entry Deadline Extended:
16 June 2017

www.scripawards.com
Who Can Enter
How To Enter
The Scrip Awards is open to any research-based pharmaceutical or biotech company
operating anywhere around the world, as well as to some third party / partner companies
that supply services to the pharmaceutical industry.
The Scrip Awards is free to enter.
1. Select the relevant category/ies for your business and review the entry criteria at
scripawards.com
2. Prepare your entry off-line
3. Submit your entry by 16 June online via scripawards.com (you will receive an
automated submission receipt)
Please refer to the category criteria as a guide.
The Entry Deadline has been extended to 16 June 2017.
Early Bird Deadline: Enter by 19 May 2017 to secure a 10% discount on your table.
To discuss event sponsorship opportunities please contact:
Christopher Keeling
Tel: +44 (20) 337 73183
Mobile: +44 (0) 7917 647 859
Email: christopher.keeling@informa.com

www.scripawards.com
• All entries must be written in English
• Limit your entry to 1,500 words
• All entries must be accompanied by a
250-word synopsis of the entry which
may be used in Awards publicity material
(this is in addition to the 1,500-word
entry)
• All entries must be submitted via our
online entry system
• All entries must be based on activities
undertaken from activities undertaken
since 1 June 2016 to 31 May 2017
• Answer each question under a separate
heading, as specified in the category
criteria
• Do not provide any supporting
documentation – all information should
be included within your 1,500-word entry
• Plan ahead to ensure it arrives in plenty
of time so that, should it be incomplete,
there will still be time to correct and re-
submit it before the closing date.
• All entries will be treated as confidential,
but Scrip reserves the right to publish
positive extracts from winning entries.
• All companies shortlisted as finalists
will be notified directly by Scrip by mid-
September.
• The judging panel reserve the right to
move an entry into a different category
if they feel it is better suited in this
category.
For this special Award, candidates must be
nominated by a third party. The nomination
should outline in no more than 750 words
what the nominee has accomplished
during his or her career and say why they
are worthy of this Award.
All nominations must include:
• The name of the nominee
• The job title of the nominee (if applicable)
• The company name (if applicable)
• Your contact details
• The contact details of the nominee
• A précis of up to 750 words of why you
think your nominee is worthy of receiving
the Lifetime Achievement Award.
Entry Guidelines
Multiple Entries
Lifetime Achievement Awards Nominations
Companies may enter more than one category, provided that each entry has been
specifically written to address the relevant criteria and is accompanied by a separate 250-
word synopsis.

www.scripawards.com
Best Company in an Emerging Market
Scrip’s Best Company in an Emerging Market Award seeks to reward the growing RD-based
pharmaceutical industry founded in areas beyond its traditional geographic borders of North
America, Western Europe and Japan.
This Award is open to any research-based pharmaceutical or biotechnology company that
has its headquarters in an emerging market.
The judges will be looking for excellent performance across a range of business activities
between June 1, 2016 and May 31, 2017. This could mean anything from growing sales and
profits to launching new products, or signing a transformative new deal.
Companies eligible for this Award are those based in emerging markets in Asia, central and
eastern Europe, central and south America, the Middle East and Africa.
To enter this category, please answer the following:
• Please give the name of the entering company and country where it is headquartered
• What has been this company’s most significant achievement during the year?
• Give details of what this company has achieved in terms of:
- Growth in sales and profits
- Signing important new deals
- Introducing new products onto the market
- Producing a promising new drug pipeline
- Operational improvements, particularly after restructuring, or changing the focus of the
business.
Scrip Awards 2017 Categories

www.scripawards.com
Best Technological Development in Clinical Trials – Sponsor-focused
The Scrip Awards for Best Technological Development in Clinical Trials recognize the
promising and disruptive role that digital health technology now plays in clinical drug
development. The award for Best Technological Development in Clinical Trials is split into two
this year, with categories rewarding advances that are focused on helping sponsors, and
those designed to ease the experience of clinical trial participants.
This Sponsor-focused Award recognizes the vital importance of using the most sophisticated
platforms to catalyze and optimize data gathered during clinical trials. Advances in software
and applications have a pivotal role to play at all stages of the trial process, assisting
sponsors in effective management of study logistics, monitoring, risk mitigation and timely
data collection and analysis. The judges will be looking for the product or suite of products
that help study teams better manage and oversee clinical trial activities.
All technologies launched or significantly updated between June 1, 2016 and May 31, 2017
are eligible to enter.
Companies wishing to enter must have played a role in the development of the nominated
technology, and all parties to any joint development agreements should be disclosed in the
application.
To enter this category, please provide the following:
• The name of all companies involved in the product development, including an outline of
their role(s)
• Specify the date and market of the technology’s first launch, if applicable
• Outline the key features and benefits of the technology, and how they support the clinical
trial process
• What problems does this product solve and what is novel about it?
• What is the single most significant benefit of the entrant’s technology to users?
• Give an estimate of how much the technology could save a sponsor (in US$ or time) on a
typical protocol compared with existing solutions
• If possible, please provide a link to a product demo (product webpage, YouTube video, etc.).

www.scripawards.com
Best Technological Development in Clinical Trials – Patient-focused
The Scrip Awards for Best Technological Development in Clinical Trials recognize the
promising and disruptive role that digital health technology now plays in clinical drug
development. The award for Best Technological Development in Clinical Trials is split into two
this year, with categories rewarding advances that are focused on helping sponsors, and
those designed to ease the experience of clinical trial participants.
This Patient-focused Award recognizes the development of smartphone apps, mobile health
devices, and a host of other products that are revolutionizing the way patients participate
in clinical trials. The judges will be looking for the product that represents the best advance
in improving patient data collection and/or the patient experience in clinical trials. Those
considered may include electronic patient diaries, mobile health devices or any other digital
tools that support, encourage or aid the patient’s participation in the clinical trial.
All technologies launched or significantly updated between June 1, 2016 and May31, 2017
are eligible to enter.
Companies wishing to enter must have played a role in the development of the nominated
technology, and all parties to any joint development agreements should be disclosed in the
application.
To enter this category, please provide the following:
• The name of all companies involved in the product development, including an outline of
their role(s)
• Specify the date and market of the technology’s first launch, if applicable
• Outline the key features and benefits of the technology, and how they support the
patient’s clinical trial journey
• What problems does this product solve and what is novel about it?
• What is the single most significant benefit of the entrant’s technology to users?
• Give an estimate of how much the technology could save a sponsor (in US$ or time) on a
typical protocol compared with existing solutions
• If possible, please provide a link to a product demo (product webpage, YouTube video, etc.).

www.scripawards.com
Community Partnership of the Year Award
This Award, inaugurated last year, is designed to acknowledge the numerous ways in which
pharma and biotech companies give back to the wider community. This could include
outreach within a local community, with a charity or patient advocacy group, or alongside an
NGO or humanitarian organization.
The judges will be looking for effective partnership activity that took place between June 1,
2016 and May 31, 2017 to the benefit of humankind. Types of partnerships could include, for
example, patient and carer support programs, educational programs or disease awareness
campaigns or even a social media campaign that went viral.
• Please give the name of the entering company and the name of the partnership
• Please outline the nature of the partnership being entered
• What were the aims of the partnership?
• What were the benefits of the partnership and how were they measured?
• What lessons were learned from the partnership and how might it be improved in future?

www.scripawards.com
Best Partnership Alliance – Sponsored by INC Research
Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/
or biotech companies working together to develop new medicines. This category seeks
to reward innovative partnerships between companies in which they share the risks and
rewards inherent in developing new drugs.
The judges will be focusing on deals that require strong strategic input from both partners,
involving business development, joint marketing/promotion or joint RD. They are looking for
those deals that are the most mutually beneficial, have the most strategic potential, and are
innovative in their structure.
Partnerships must have been announced, or have achieved a significant milestone, between
June 1, 2016 and May 31, 2017 and entrants should be able to show some sustained
benefits from the deal. NB: Deals between majority or wholly owned subsidiaries and their
parent companies are not eligible for this Award.
• Please give the name of company/organizations involved
• Please outline the structure of the partnership, detailing the parties involved, what it covers
and the responsibilities on both sides
• Does its structure represent an innovative business model, and if so how? How does it
demonstrate that either party was the “partner of choice”?
• Please summarize the strategic potential of the deal, and if applicable the milestone
reached
• Please explain how the deal is mutually beneficial to both parties
• What aspect of the deal makes it unique or particularly special?
• How does the collaboration hope to meet any unmet medical need?
IMPORTANT NOTE
Would your deal fit better into the Licensing Deal of the Year category? Please check before
you enter.

www.scripawards.com
Financing Deal of the Year
This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech
companies. The investment can come in a variety of guises from grants and public-private
partnership deals to venture fundraising and public offerings, but should be earmarked for
use in drug discovery and/or development.
In making their decision, the judges will scrutinize entrants on their fundraising strategy,
amount raised, the structure of the deal, and on how the money will be used. This Award is
open only to companies actually raising the funds (i.e., not bankers or agents). To be eligible,
all financing must have been announced between June 1, 2016 and May 31, 2017.
To enter this category, please answer the following questions:
• Please outline the form of the financing, how much money was raised (including how
this compares with the company’s capital base), and how close was this to meeting your
fundraising objectives?
• Please explain how this source of financing was best suited to your purposes
• Please describe how this fundraising was particularly creative. Has this set a precedent that
has since been repeated?
• Did the funding succeed in other ways, such as bringing on board a new kind of investor?
• How will the money be used?
• Please give evidence of early value creation from the deal.

www.scripawards.com
QuintilesIMS’ Clinical Advance of the Year Award
This Award seeks to recognize success in a clinical trial of a new drug product (biological or
chemical) that is expected to lead to an advance in healthcare. This might include the first
demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a
pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a
potential new or expanded indication for an already marketed product.
Unlike the Best New Drug Award, the product involved need not yet be approved, but as
with that award the judges will be looking for innovation, clear proof of benefit and potential
commercial reward.
To be eligible, the study in question must have been presented for peer review at a major
medical meeting or been published in a scientific journal between June 1, 2016 and May 31,
2017.
Entrants must have played a role in the clinical study, and all joint parties must be disclosed
in the application.
To enter this category, please answer the following questions:
• Please give full details of the study, i.e., its name (protocol ID, trial identifier), Phase,
disease type and patients segment studied, sponsors, and the primary drug tested
• Please summarize the major findings of the study, including all primary/co-primary and
main secondary endpoints, and safety endpoints
• How does the drug work in the setting tested?
• How do these findings represent a potential leap forward in therapy, or fulfil an unmet
medical need?
• What could be the potential market size of this breakthrough?

www.scripawards.com
Licensing Deal of the Year – Sponsored by Worldwide Clinical Trials
Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating
income for smaller firms. Deals considered here are those that involve the licensing of a
particular drug, project or group of drugs/projects from one company to another for further
development and/ or marketing. (NB It does not include more involved partnerships between
companies to explore particular therapeutic strategies (see criteria for the Best Partnership
Alliance Award).)
In choosing the winner of Scrip’s Licensing Deal of the Year Award, the judges will look at
all aspects of the submitted transactions, from their monetary and strategic value, to the
benefits they give to both sides. To qualify, licensing deals must have been closed between
June 1, 2016 and May 31, 2017.
• Please outline the structure of the deal, giving the names of the parties involved, the drug
candidate(s) concerned, and what rights it covers
• What is the monetary value of the deal in up-front and milestone payments?
• What is the geographic spread of the deal? Does it allow any party to enter new markets?
• What is the strategic value of the licensed product to the licensee’s business?
• Please explain how the licensed product was the best possible candidate to complement
the rest of the licensee’s pipeline or particular disease franchise.
IMPORTANT NOTE
Would your entry fit better in the Best Partnership Alliance category? Please consider before
you enter.

www.scripawards.com
Executive of the Year – Sponsored by Lachman Consultants
Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership
of large and small pharmaceutical and biotechnology companies. This year’s winner will be
the executive who has exhibited exemplary leadership throughout the year from June 1,
2016 to May 31, 2017.
This could range from leading an emerging company to an established place within the
industry, to turning around the fortunes of a failing company or unit, or leading a firm
successfully through the turbulence of a merger or acquisition. Also important to the judges
will be the executive’s career achievements, influence within the industry and leadership
qualities.
To be eligible for this year’s Award, entrants must hold a C-suite executive position.
Candidates must be employed by the company at the time of nomination.
• Please give the name, company and position of the entrant, and the date of taking up this
post
• What have been the entrant’s greatest achievements during the qualifying year? What has
been the direct consequence of these on company performance?
• How have these achievements strengthened the candidate’s influence within the industry?
Please give examples
• What are the entrant’s greatest strengths as a leader? Please show how these have had a
bearing on their achievements this year
• What specific previous accomplishments did the entrant have that made them perfectly
fitted to achieving this success? For example, previous scientific or management
experience.

www.scripawards.com
Best Contract Research Organization – Full-Service Providers
The Scrip Awards for Best Contract Research Organization acknowledge the critical role that
CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry
seeks to benefit more and more from these specialist companies’ experience in handling all
aspects of clinical trials.
This year the award has been split into two categories to separate the full-service providers
from those smaller CROs that provide niche services to their clients.
Today, the role of the CRO has gone beyond the traditional model of service-level agreements
to offer bespoke clinical trial strategies and CROs are increasingly engaged in risk-sharing
partnerships or acting as a single-source developer while also remaining committed to core
strengths.
This Award for those companies who provide the full range of services to their clients will be
judged on the quality of services and relationships they have built with their clients. It will
pay particular attention to the innovative patient recruitment strategies the CRO has brought
to the deal.
To qualify, candidates must draw on their achievements in the year between June 1, 2016
and May 31, 2017.
• What particular capabilities and strengths does the CRO offer?
• How has this firm delivered results that exceed sponsor expectations?
• What innovations in patient recruitment strategy has the CRO brought to its partner?
• How has it improved its performance, for example, in its quality of data, timelines and
transparency?
• What steps is the company taking towards streamlining data collection and reporting?

www.scripawards.com
Best Contract Research Organization – Niche Providers
The Scrip Awards for Best Contract Research Organization acknowledge the critical role that
CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry
seeks to benefit more and more from these specialist companies’ experience in handling all
aspects of clinical trials.
This year the award has been split into two categories to separate the full-service providers
from those smaller CROs that provide niche services to their clients.
This Award for those companies who provide niche services to their clients will be judged on
the quality of services and relationships they have built with their clients.
To qualify, candidates must draw on their achievements in the year between June 1, 2016
and May 31, 2017.
• What particular capabilities and strengths does the CRO offer?
• How has this firm delivered results that exceed sponsor expectations?
• What innovations has the CRO brought to its partner?
• How has it improved its performance, for example, in its quality of data, timelines and
transparency?
• What steps is the company taking towards streamlining data collection and reporting?

www.scripawards.com
WuXi AppTec’s Biotech Company of the Year Award
The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed
the research and development of medicines in the past few decades. This award honors
outstanding achievement by biotech companies over the qualifying 12 months.
The winner of the Biotech Company of the Year Award will be the biotech firm that has
achieved the most in the 12 months between June 1, 2016 and May 31, 2017. This could be
in terms of moving the business from an early stage to a more mature company, signing a
transformative deal, taking its first or a major new product towards the market, or raising
significant new funds.
• Name of entering company
• What has been the company’s most significant achievement during the year?
• Give details of what the firm has accomplished over the year in terms of:
- Bringing new products closer to their first markets
- Raising funds
- Signing significant licensing or partnership deals
- Showing strong management not afraid of making hard decisions
- Using proprietary science or technologies to address an unmet medical need
- Successfully transforming the business from an early stage to a more mature company.

www.scripawards.com
Business Development Team of the Year
Scrip’s Business Development Team of the Year Award will honor the achievements of
business development teams whether they are from a pharma or biotech company or a
cross-company team responsible for a specific deal or collaborative project.
This Award will go to a team that is truly much more than the sum of its parts. The judges
will be looking for strong performance across a number of criteria, such as achievement of
short and long-term goals, and good communication of a shared vision.
• Please give details of the company(ies), the particular team being entered and its core
function
• Please describe the team’s goals and vision, and how these are communicated
• What was the greatest achievement of the team during the year between June 1, 2016
and May 31, 2017?
• Please describe how all parts of the team were fully aligned to achieve this, including how
supporting functions, such as HR, finance and IT, were integrated into the team
• Rate the team, giving justification, according to the following criteria:
- Achieving short-term and long-term goals
- Managing resources
- Providing a platform for professional development and teamwork
- How does the team embody a management model that others should follow?

www.scripawards.com
HUYA Bioscience International’s Best New Drug Award
The Best New Drug Award recognizes excellence in pharmaceutical development. Launching
innovative new products is the most important function of the industry, and a successful
new drug launch marks the culmination of years of risky and expensive RD.
In this category, the judges will be looking for the small-molecule or biological product that
was approved in its first market worldwide during the qualifying period that represents the
best therapeutic advance in its area.
All recently launched new active substances, including small-molecules, biologicals or
vaccines, are eligible to enter as long as they were first licensed in any market between June
1, 2016 and May 31, 2017. Generic and biosimilar products are not eligible for this award.
Entrants must have played a role in the development of the nominated product, and all
parties to joint ventures should be disclosed in the application.
• Please give the trade and generic name of the entrant, the therapeutic indication for which
it is being considered, and the company(ies) involved in its development (if more than one
company, please detail the relationship between the parties)
• What was the date and market of the candidate’s first approval and launch?
• Please explain the mechanism of action of the candidate. How does this represent a step
forward in treatment in this therapeutic area?
• Please outline the evidence for the product’s clinical activity. How does its activity translate
into a meaningful therapeutic benefit for patients, and how is this benefit over and above
that provided by other treatments in this area?
• How does the entrant address an unmet medical need?
• What is the potential market size of the candidate?

www.scripawards.com
PPD’s Pharma Company of the Year Award
The Pharma Company of the Year Award honors outstanding achievement by pharmaceutical
companies over the qualifying 12 months, June 1, 2016 and May 31, 2017. This special
award is chosen by Scrip’s senior editorial team, based on a variety of key metrics:
• Financial performance in 2016 compared with the previous year
• Strategic advances, looking at its most significant achievements over the year
• Progress in the emerging markets
• New product launches including line-extensions and formulations
• Advances in the drug pipeline, including major clinical trial reports.

www.scripawards.com
Scrip’s Lifetime Achievement Award
The winner of this Award will be an exceptional individual with a consistent history of service,
above and beyond the call of duty, throughout their career.
This prestigious international Award will go to someone who has had a distinguished career
in the biotech or pharmaceutical arena, primarily within industry. Nominees may be retired
or semi-retired but will still be active in the industry in some capacity. For this special Award,
candidates must be nominated by a third party.
The nomination should outline in no more than 750 words what the nominee has
accomplished during his or her career and say why they are worthy of this Award.
All nominations must include:
• The name of the nominee
• The job title of the nominee (if applicable)
• The company name (if applicable)
• Your contact details
• The contact details of the nominee
• A précis of up to 750 words of why you think your nominee is worthy of receiving the
Lifetime Achievement Award.

www.scripawards.com
The Scrip Awards will culminate in a gala black-tie dinner and awards
ceremony on Wednesday 29 November at the London Hilton on Park Lane. For security
purposes, attendance at the event is by ticket only and guests are required to provide some
personal details beforehand. All shortlisted companies and individuals are required to attend
the Awards ceremony.
To discuss event sponsorship opportunities please contact:
Christopher Keeling
Tel: +44 (20) 337 73183
Mobile: +44 (0) 7917 647 859
Email: christopher.keeling@informa.com
Or visit www.scripawards.com
• Read the entry details and judging criteria carefully for each category before starting your
submission
• Write your entry specifically for the category in question, check the nomination is in the
correct category and would not stand a better chance of winning in a different category
• Do not exceed the word limits. Entries should be 1,500 words, executive summaries 250
words, and there should be no supporting material
• Ensure the activities included were undertaken between the date parameters, 3 June 2016
to 31 May 2017
• Ensure each entry meets the specific criteria for its category
• Ensure you have answered each entry question under a separate heading in your
submission
• Plan ahead to ensure it arrives in plenty of time so that, should it be incomplete, there will
still be time to correct and re-submit it before the closing date of 16 June 2017.
How Are The Scrip Awards Presented?
Useful Tips For A Winning Entry

www.scripawards.com
Dr Laura Brown
Director, LB Training and Development
Brown is an independent pharmaceutical project management, QA and
training consultant, and course director for the MSc programme in clinical
research at the University of Cardiff’s School of Pharmacy. She has more
than 20 years of experience of managing clinical development projects,
and training in the pharmaceutical industry. She has worked in project
management for several companies including Wellcome, Hoechst Marion
Roussel, Good Clinical Research Practices and LB Training and Development.
She is also co-author of several books including, Project Management for the
Pharmaceutical Industry.
Clive Dix
CEO, C4X Discovery
Dix is one of the UK’s leading pharma and biotech entrepreneurs. He has
more than 25 years’ experience life sciences, with over 20 years in senior
pharmaceutical industry positions, and a degree and PhD in Pharmacology.
Dix is currently CEO of C4X Discovery plc and Chairman of Centauri
Therapeutics Ltd and Touchlight Ltd, and is also a non-executive director
of the Medicines Discovery Catapult. Dix was formerly co-founder and
chief executive of Convergence Pharmaceuticals Ltd., a pain-specialist
pharmaceuticals company acquired by Biogen Idec in 2015. Previously he
had been a founder and CEO of PowderMed Ltd, and chair of Auralis Ltd.
Before that Dix was held RD roles at PowderJect Pharmaceuticals plc until
its acquisition by Chiron Vaccines in 2003, and GlaxoWellcome.
Scrip Awards 2017 Judging Panel

www.scripawards.com
Laurie A. Halloran
President, Halloran Consulting
Halloran is the president of Halloran Consulting Group, founded in 1998. With
over 30 years in life science management, she has become recognized as an
industry expert through her group’s work in bringing world-class expertise
to plan and build early-stage life science companies, and to transform and
restore large life science companies to nimble and high quality organizations.
In 2017 Halloran was awarded Enterprising Woman of the Year and in
2015, Halloran was honored by the Boston Business Journal as a Woman
of Influence. The company has received a ranking in the INC 500 fastest
growing companies for the past three years. In 2010, Halloran was selected
as one of the 100 Most Inspiring People in Life Science by PharmaVoice and
in 2009, she was awarded clinical researcher of the year by ACRP.
Dennis Gillings
Co-founder and former Executive Chairman, Quintiles
Gillings is recognised as a visionary pioneer in the contract research
organisation industry. He is co-founder and former executive chairman
of Quintiles Transnational, the world’s largest biopharmaceutical services
company. Gillings retired as executive chairman in 2015, although he
remains on the board of the Fortune 500 company.
In 2014, Gillings was appointed World Dementia envoy by former UK Prime
Minister David Cameron. In this capacity he chaired the World Dementia
Council, an organization that seeks to stimulate innovation to treat cognitive
decline.
As envoy, he worked with governments to provide a global leadership role
in addressing the economic, regulatory and social barriers to innovation
in dementia prevention, treatment, and care. Gillings has seen firsthand
the devastating effects of dementia and lack of effective treatment, as his
mother lived with the condition for 18 years until her death in 2013.
Prior to founding Quintiles, Gillings was a professor of biostatistics at the
University of North Carolina at Chapel Hill for more than 15 years. Among
the many honours he has received, Gillings was awarded a CBE in 2004 for
services to the pharmaceutical industry.

www.scripawards.com
Professor Trevor M Jones CBE
Chair, Simbec-Orion Group, and Director, Arix Bioscience
Jones is chair of Simbec-Orion Group and Director Arix Bioscience plc. He was
formerly RD director of The Wellcome Foundation, a director of Allergan
Inc. and director general of the Association of the British Pharmaceutical
Industry (ABPI). He is a visiting professor at King’s College, London
Brian Hargreaves
Independent Adviser
Hargreaves is an independent adviser for private equity. His career in
healthcare spans academia, pharma, venture capital and private equity.
Following his early career as a lecturer in pharmacy at Manchester University,
he had a series of commercial and international marketing roles with Smith
Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra
Hässle which included the commercialisation of the blockbuster Nexium. In
1997, he moved to 3i plc in the innovative growth period of biotech venture
capital. More recently he originated several significant growth capital deals
and buyouts.
Hargreaves currently advises selected private equity firms and spends a
proportion of his time in the charity sector.

www.scripawards.com
Dr Alison Messom
Chair, Institute of Clinical Research, and Director, ALM Consultancy
Since 2012, Messom has been chairman of the Institute of Clinical Research;
the oldest independent membership-led professional body for global
clinical researchers. With a background in molecular genetics, Messom has
almost 20 years’ industry experience working both within pharmaceutical
companies and clinical research organisations. 
Messom has detailed experience of directing global clinical trials and has
worked in a wide variety of leadership roles, within pharma companies and
CROs not only for project and monitoring teams, but also data management,
outsourcing, informatics and translational medicine departments. Most
recently she has provided consultancy support to an academic group
working on a translational medicine project and operational consultancy to a
mid-sized pharma company working in Phase III and IV.
Viren Mehta
Founder, Mehta Partners
Mehta founded and is managing member of Mehta Partners, LLC. His
analytical insights on global healthcare have influenced bio-pharmaceutical
strategy and investments worldwide. Educated at the University of Southern
California and UCLA, he has worked with senior biopharma leaders and
investment managers for over 30 years.
Mehta’s career began with Merck Co. in international strategic planning
and competitor analysis. This foundation prompted Wood MacKenzie
Company Inc. to invite him to establish a pharmaceutical research function
in New York. This effort was expanded at S.G. Warburg Company, and led
to the formation of the BioPharma investment advisory group Mehta and
Isaly, now known as Mehta Partners.
Gather Health is Mehta’s new initiative to empower patients while enhancing
physician productivity. Gather Health brings together healthcare providers
and patients’ social networks, enabling patients to get real-time and active
resources and motivation to improve outcomes.

www.scripawards.com
Peter Pitts
President, Center for Medicine in the Public Interest
Pitts is president of the Center for Medicine in the Public Interest. A former
member of the United States Senior Executive Service, Pitts was the
FDA’s associate commissioner for external relations, serving as senior
communications and policy adviser to the commissioner. He supervised the
FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special
Health Issues, Office of Executive Secretariat, and Advisory Committee
Oversight and Management. He served on the agency’s obesity working
group and counterfeit drug taskforce and is a Special Government Employee
consultant to the FDA’s Risk Communications Advisory Committee.
His specific areas of global policy expertise include FDA policy and process,
healthcare technology assessment and reimbursement issues, biosimilar
development, Rx-to-OTC switching, risk management plans, GMP policies,
pharmacy education programs, drug safety, DTC/ItP, Critical Path,
personalized medicine, clinical trial transparency, IP protection, FDA reform,
drug importation, counterfeiting, genetically modified food issues, food
safety and security, recalls, and nutritional labeling.
Phornvit Phacharintanakul
Chair, Strategic Business Partners
Phacharintanakul is chair of Strategic Business Partners in Bangkok, Thailand.
Until the end of 2004 he was chair of the board at Aventis Thailand,
where he previously held a range of posts including managing director
and marketing manager. Before joining Aventis, he was on the secretariat
of the United Nations Economic Commission for Asia and the Pacific.
Phacharintanakul also acts as an expert advisor for the Thailand Center of
Excellence for Life Sciences.

www.scripawards.com
Raymond F. Schinazi
Schinazi is the Frances Winship Walters Professor of Pediatrics and Director
of the Laboratory of Biochemical Pharmacology at Emory University and
co-Director of the HIV Cure Scientific Working Group for the NIH-sponsored
Emory University Center for AIDS Research. Schinazi has authored over
500 peer-reviewed papers and seven books and holds over 100 issued US
patents, which have resulted in 15 NDAs.
A world leader in nucleoside chemistry, Schinazi is best known for his
pioneering work on HIV, HBV and HCV drugs stavudine, lamivudine,
emtricitabine, telbivudine, and most recently sofosbuvir. More than 94% of
HIV-infected individuals in the US on combination therapy take at least one
of the drugs he invented.
After 35 years of service, Schinazi retired from the Department of Veterans
Affairs with his latest position as senior research career scientist. Schinazi
was appointed to the Global Virus Network executive committee in 2016.
Andy Smith
Senior Principal, Pricing Market Access, Commercialisation and Outcomes,
ICON PLC
Smith began his career as a scientist in the research and development
division of ICI and then SmithKline Beecham. After completing his PhD in
Molecular Biology at the University of Nottingham and with Glaxo, after
then an MBA, Smith switched to a commercial role at SB Pharmaceuticals
and was appointed global brand manager for Bactroban and new products
in the Anti-Infectives Global Marketing Group. In 2000, Smith moved into
asset management and venture capital at 3i Group and subsequently held
the position of lead fund manager for three life science specific funds – 3i
Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and
AXA Framlington Biotech Fund. Smith was awarded the Techmark technology
fund manager of the year for 2007.
After leaving AXA in 2010, Smith held appointments as director of business
development at the Oxfordshire Bioscience Network and head of corporate
finance at PharmaVentures. Smith has also taught the life science company
valuation, finance and analysis module on the University of Cambridge MPhil
program for over ten years. Smith returned to specialist fund management
in 2012 to manage the Magna Biopharma Income Fund.
In 2017 Andy moved to the Pricing Market Access group at ICON in London
where he advises big pharma and smaller life science companies on the
valuation and commercialisation of their products.

www.scripawards.com
Dr Brian Tempest
Chair, Hale Tempest Co Ltd, and Editor, Journal of Generic Medicines
Tempest has worked in the pharmaceutical industry for the last 46 years and
in that time has managed healthcare businesses around the globe. Between
1995 and 2007 he held senior executive positions, including president, CEO
and vice-chairman at Ranbaxy Laboratories. Previously, Tempest was Far
East regional director for GlaxoSmithKline in the Far East, Middle East and
Africa. Today, as Chairman of Hale Tempest, he advises companies, banks,
investment funds, private equity and high net-worth individuals on their
strategy in Asia. Tempest is a non-executive director of SRL Diagnostics,
Fortis Healthcare, Touch Digital Media, Religare Capital Markets and Glenmark
Pharmaceuticals. Currently he is Editor of the Journal of Generic Medicines
and a non-executive director of the United Nations Medicines Patent Pool.
Robert Spiegel
Founder, Spiegel Consulting
Spiegel is the founder of Spiegel Consulting, an independent advisory firm to
pharma and biotechnology companies. He retired in 2009 as chief medical
officer at Schering-Plough. With more than 25 years of experience in the
pharmaceutical industry he played a significant role in the development
of novel biologics and drugs as senior vice-president of Worldwide Clinical
Research. Spiegel is a fellow of the American College of Physicians and has
received numerous awards and fellowships.
He serves as an advisor to Warburg Pincus and the Israeli Biotech Fund
and on the boards of numerous biotechnology companies and non-profit
organizations. He is an assistant professor Weill Cornell Medical School and
associate fellow in the University of Pennsylvania Center for Bioethics.

www.scripawards.com
Robert Thong
Independent Consultant and Writer
Thong consults on business strategy and collaborations in the bioscience
sector, and writes a regular blog on these topics, SciTechStrategy. Thong’s
full-length book, Biopharma RD Partnerships: From David Goliath to
Networked RD, was published in January 2016, derived from the practical
experiences of over forty different organisations. He has previously been
co-head of the Cap Gemini Life Sciences Group, managing director of
Datamonitor’s healthcare division, a non-executive board member of the
listed US mid-sized pharmaceutical company Alpharma, and a co-founder of
two specialist consultancies focusing respectively on mid-sized biopharma
companies and change management for scientific organisations.
Sir Gregory Winter
Master, Trinity College Cambridge
Winter is the Master of Trinity College, Cambridge and a Fellow of the Royal
Society and until recently a member of the Medical Research Council’s
Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist,
inventor and entrepreneur and best known for his research and inventions
relating to therapeutic antibodies made at the LMB.
He has founded three biotech companies based on his inventions: Cambridge
Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000
(bought by GlaxoSmithKline) and Bicycle Therapeutics in 2009.

www.scripawards.com
The Scrip Awards prides itself on its Judging Panel, comprised of independent, senior industry
experts from around the world, each chosen for their knowledge, objectivity and credibility.
The judges separately consider entries from those categories that are relevant to their
particular areas of specialist knowledge, expertise and experience, ensuring a considered
response to every individual submission. Each category is reviewed by at least three judges.
The judges mark each entry against the published criteria for its category, and the scores are
marked out of five for each category answer. These are then collated by the Scrip Awards
team to determine which entries are included in the shortlist, and the ultimate winner.
The chair of the Judging Panel reserves the right to cast any deciding vote, should the need
arise. The judges’ decision is final and neither the organisers nor the Judging Panel will enter
into any correspondence about the results. Judging will take place throughout July, and the
shortlist will be announced in early September. Details of the winners are strictly embargoed
until the night but further details of all of the shortlisted entries will be published in Scrip in
the weeks leading up to the ceremony on Wednesday 29 November at the London Hilton on
Park Lane.
How Do The Judges Select The Awards
Winners?
Informa, organizer of the Scrip Awards, recognizes and respects the sensitive nature of
the information submitted in the entries. We ensure that this recognition is shared by our
Judging Panel and therefore require each judge to sign a confidentiality agreement before
they are appointed. Entries are not disclosed or discussed outside the judging process. The
Judging Panel for each Award is selected to avoid any conflict of interest. Once an entry is
shortlisted, extracts from the entry summary only will be sourced for inclusion in the Awards
ceremony and any subsequent editorial coverage. Please ensure your entry summary
contains no confidential or sensitive information.
Confidentiality

Scrip Awards 2017 Entry Guide

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Scrip Awards 2017 Entry Guide

Similar to Scrip Awards 2017 Entry Guide (20)

More from Pharma Intelligence

More from Pharma Intelligence (10)

Recently uploaded

Recently uploaded (20)

Scrip Awards 2017 Entry Guide